AR100608A1 - CITOMEGALOVIRUS COMPLEXES AND USES OF THE SAME - Google Patents

CITOMEGALOVIRUS COMPLEXES AND USES OF THE SAME

Info

Publication number
AR100608A1
AR100608A1 ARP150101642A ARP150101642A AR100608A1 AR 100608 A1 AR100608 A1 AR 100608A1 AR P150101642 A ARP150101642 A AR P150101642A AR P150101642 A ARP150101642 A AR P150101642A AR 100608 A1 AR100608 A1 AR 100608A1
Authority
AR
Argentina
Prior art keywords
complexes
citomegalovirus
same
pentameric
proteins
Prior art date
Application number
ARP150101642A
Other languages
Spanish (es)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR100608A1 publication Critical patent/AR100608A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Abstract

La presente divulgación proporciona proteínas gL de citomegalovirus (CMV) modificadas y complejos que comprenden proteínas gL, en particular complejos pentaméricos que comprenden gH, gL, pUL128, pUL130, pUL131. La divulgación también proporciona procedimientos de purificación de complejos pentaméricos y de reducción de complejos diméricos contaminantes que consisten en gH y gL. También se proporcionan usos de complejos pentaméricos en composiciones inmunógenas y vacunas.The present disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins, in particular pentameric complexes comprising gH, gL, pUL128, pUL130, pUL131. The disclosure also provides procedures for purification of pentameric complexes and reduction of contaminating dimeric complexes consisting of gH and gL. Uses of pentameric complexes in immunogenic compositions and vaccines are also provided.

ARP150101642A 2014-05-27 2015-05-26 CITOMEGALOVIRUS COMPLEXES AND USES OF THE SAME AR100608A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14170137 2014-05-27

Publications (1)

Publication Number Publication Date
AR100608A1 true AR100608A1 (en) 2016-10-19

Family

ID=50884237

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101642A AR100608A1 (en) 2014-05-27 2015-05-26 CITOMEGALOVIRUS COMPLEXES AND USES OF THE SAME

Country Status (3)

Country Link
AR (1) AR100608A1 (en)
BE (1) BE1023213B1 (en)
WO (1) WO2015181142A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
JP6980780B2 (en) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド Human cytomegalovirus vaccine
WO2018193307A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
MX2021004273A (en) 2018-10-17 2021-12-10 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes.
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (en) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 Human cytomegalovirus gb polypeptide
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Also Published As

Publication number Publication date
BE1023213B1 (en) 2016-12-21
WO2015181142A1 (en) 2015-12-03
BE1023213A1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
AR100608A1 (en) CITOMEGALOVIRUS COMPLEXES AND USES OF THE SAME
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
BR112018005779A2 (en) htt repressors and uses thereof
JO3765B1 (en) Therapeutic HPV18 vaccines
MX2021001053A (en) Influenza virus vaccines and uses thereof.
BR112017011215A2 (en) pro-flavoring distribution particles
MX2020005187A (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof.
DK3244917T3 (en) Immunogenic compositions for use in pneumococcal vaccines
MX2017009538A (en) Cytomegalovirus antigens and uses thereof.
MX2017002438A (en) Topical formulation.
CL2015001733A1 (en) Compounds derived from fused aryl and heteroaryl lactams, modulators of ezh2; pharmaceutical composition that includes them; use of the compound for the treatment of cancer.
MY181175A (en) Therapeutic hpv16 vaccines
MX2019013670A (en) Antibody and protein formulations.
DK3570879T3 (en) Immunogenic compositions for use in pneumococcal vaccines
BR112017025711A2 (en) "compositions, process for preparing polyether modified siloxanes and use of innovative compositions"
CL2017000984A1 (en) Reduction of the viscosity of pharmaceutical formulations
TR201910866T4 (en) Combined preparations for cancer treatment.
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
CY1119532T1 (en) (S) -PYRILDOL AND THE PHARMACEUTALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
CY1121105T1 (en) PHARMACEUTICAL FORM OF ATAZANAVIR AND COMBISSTATIS FOR HIV TREATMENT
MX2019005102A (en) Synthetic chimeric poxviruses.
TR201820050T4 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors.
EP3149471A4 (en) Improvements in using blood culture platforms for commercial sterility tests
BR112016022787A2 (en) method for inducing an immune response in a human subject, immunogenic composition, and use of a second immunogenic composition
PH12017500602A1 (en) Methods for treating ocular conditions

Legal Events

Date Code Title Description
FB Suspension of granting procedure